Retrospective ED study links two drugs to fewer short-term returns than…

Comparative Effectiveness of Haloperidol, Droperidol, and Ondansetron for Cannabinoid Hyperemesis Syndrome in the Emergency Department.

Academic emergency medicine : official journal of the Society for Academic Emergency Medicine • • Observational • Highly Relevant
🤖

AI Summary

This multicenter retrospective cohort study compared haloperidol, droperidol, and ondansetron among adults treated in emergency departments for vomiting and cannabis-related diagnoses consistent with suspected cannabinoid hyperemesis syndrome (CHS). The main outcome was returning to the ED within 72 hours. After propensity-score matching, 72-hour returns were less frequent with haloperidol than ondansetron (8.2% vs. 15.1%) and with droperidol than ondansetron (7.4% vs. 14.0%). These are observational associations, not proof that either medication caused fewer returns.

There was no statistically significant difference in 72-hour returns between droperidol and haloperidol. The study also reports that coded adverse events were rare across all medication groups, but it cannot establish comparative safety in detail. Because this was a retrospective study of patients identified through diagnostic codes, it cannot confirm CHS diagnoses or determine the best medication strategy. This is an abstract-based summary; the authors call for prospective studies.

💡 Key Findings

1
In matched comparisons, 72-hour ED recidivism was lower with haloperidol than ondansetron (8.2% vs. 15.1%).
High
80%
2
In matched comparisons, 72-hour ED recidivism was lower with droperidol than ondansetron (7.4% vs. 14.0%).
High
80%
3
Droperidol and haloperidol did not differ significantly in 72-hour ED recidivism.
High
80%
4
Coded adverse events were rare across all groups; this retrospective study supports further prospective research but cannot establish which treatment is best or prove that medication choice caused the differences in returns.
Good
75%

📄 Original Abstract

BACKGROUND: Cannabinoid hyperemesis syndrome (CHS) is an increasingly frequent emergency department (ED) presentation. Although ondansetron is commonly used, emerging evidence suggests haloperidol and droperidol may provide more effective symptom control. Robust comparative effectiveness data, particularly regarding short-term ED recidivism, remain limited. METHODS: We conducted a multicenter retrospective cohort study using the TriNetX Research Network from 2014 to 2024. Adults presenting to the ED with vomiting-related and cannabis-related ICD-10 diagnoses who received haloperidol, droperidol, or ondansetron during the index encounter were included. Patients with alternative causes of vomiting or major confounding conditions were excluded. Propensity-score matching was performed for three pairwise comparisons: haloperidol versus ondansetron, droperidol versus ondansetron, and droperidol versus haloperidol. The primary outcome was 72-h ED recidivism. Secondary outcomes included 72-h hospital admission, 7-day ED recidivism, and coded adverse events. Multivariable Cox proportional hazards modeling evaluated independent predictors of 72-h ED recidivism. RESULTS: After matching, haloperidol was associated with lower 72-h ED recidivism compared with ondansetron (8.2% vs. 15.1%; OR 0.50, 95% CI 0.41-0.62; p < 0.0001). Droperidol was also associated with lower 72-h ED recidivism compared with ondansetron (7.4% vs. 14.0%; OR 0.49, 95% CI 0.32-0.76; p = 0.0014). Droperidol and haloperidol did not differ significantly in 72-h ED recidivism (7.5% vs. 9.8%; OR 0.75, 95% CI 0.47-1.20; p = 0.23). In the multivariable model, haloperidol (HR 0.62, 95% CI 0.49-0.79) and droperidol (HR 0.68, 95% CI 0.56-0.83) were independently associated with lower return risk, whereas ondansetron was not. Coded adverse events were rare across all groups. CONCLUSIONS: In this large multicenter cohort, haloperidol and droperidol were associated with lower short-term ED recidivism than ondansetron among adults meeting a suspected CHS phenotype. These findings support prospective studies evaluating haloperidol and droperidol for ED management of CHS, including optimal dosing, route, medication sequencing, discharge treatment, and safety monitoring.

Explore More Research

Stay informed about the latest cannabis science.

Your stash, decoded.